OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
OrthoPediatrics (Nasdaq: KIDS) will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.
Investors can access a live and archived webcast on the company's Investors page in the Events & Presentations section; the replay will be available for at least 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – KIDS
In the Feb 13 session, KIDS gained 1.02%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Regulatory clearance | Positive | -1.9% | FDA 510(k) clearance expanding iotaSOFT use to younger patients. |
| Jan 12 | Prelim results & guidance | Positive | +9.8% | Record preliminary 2025 revenue and introduction of 2026 revenue guidance. |
| Nov 13 | Product launches | Positive | -0.4% | Launch of two PediHip bracing systems for pediatric hip conditions. |
| Nov 04 | Investor conferences | Neutral | -1.3% | Participation in several healthcare investor conferences with webcast access. |
| Oct 28 | Q3 2025 earnings | Positive | -0.3% | Q3 revenue growth and higher adjusted EBITDA alongside ongoing net losses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent divergence where shares traded flat to lower on generally positive operational and financial updates.
Over the last several months, KIDS reported multiple growth-oriented updates. On Jan 12, 2026, it announced record preliminary 2025 revenue of $236.1M with 15% growth and issued 2026 revenue and EBITDA guidance, and the stock rose 9.83%. Other news—such as FDA 510(k) clearance for the iotaSOFT system, new PediHip bracing launches, and Q3 2025 results with higher revenue and EBITDA—saw mild negative price reactions, highlighting a tendency for good news to be met with muted or slightly negative trading.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARSAW, Ind., Feb. 12, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. OrthoPediatrics will host a conference call on Thursday, February 26, 2026 at 4:30 p.m. ET to discuss the results.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for replay for at least 90 days after the event.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 85 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406
